Serum Cystatin C is a Potential Endogenous Marker for the Estimation of Renal Function in Male Gout Patients with Renal Impairment by Choe, Jung-Yoon et al.
INTRODUCTION
Until now, the glomerular filtration rate (GFR) was con-
sidered the best overall method of estimating the renal func-
tion of subjects (1). The determination of urinary clearance
of exogenous substances, such as inulin, 99mTc-DTPA, and
51Cr-EDTA, has traditionally been considered the ideal stan-
dard method for estimating accurate GFR (2). Even though
methods using exogenous substances are accurate, these pro-
cedures cannot be easily applied in clinical practice because
of the need for continuous exogenous substance infusions,
frequent urine samplings, and high cost. To overcome these
limitations, formulas to estimate or predict ‘true GFR’ using
serum creatinine levels were developed. Two commonly used
representative formulas for the assessment of GFR in adults
are the Modification of Diet in Renal Disease Study (MDRD)
equation (3) and the Cockcroft-Gault (C&G) equation (4). 
Cystatin C is a member of the family of cysteine protease
inhibitors. It has a low molecular weight of only 13 kDa and
is produced by all nucleated cells at a stable rate. Cystatin C
was first discovered as a promising endogenous marker for
GFR in 1985 (5, 6). It is wholly filtered through the glomeru-
lus and then reabsorbed, being successively metabolized with-
out secretion in the proximal tubule. Dharnidharka et al. (7)
performed a meta-analysis of 46 cystatin C-related studies to
evaluate the superiority of cystatin C levels over serum crea-
tinine levels. These authors determined that serum cystatin
C is a more potent marker of GFR than serum creatinine.
Recently, Herget-Rosenthal and his colleagues found that
determining cystatin C levels is a more sensitive test for the
early detection of renal function impairment or reduced GFR
(1). It has been recognized that an increase in serum cystatin
C might well reflect changes in renal function or GFR for
renal injury in diverse clinical conditions or diseases, includ-
ing nephropathy associated with type 2 diabetes mellitus (8),
hypertensive nephropathy (9), solid organ transplantation
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Serum Cystatin C is a Potential Endogenous Marker for the Estimation
of Renal Function in Male Gout Patients with Renal Impairment
Serum creatinine level is the most commonly used indices for assessment of glo-
merular filtration rate (GFR), even though these indices have been shown to have
some limitations in clinical practice. We investigated the diagnostic efficacy of serum
cystatin C compared to that of serum creatinine levels and identified the relating
factors associated with changes in serum cystatin C levels in gout patients with renal
impairment. A total of 68 gouty patients with renal impairment were enrolled in this
study. Diagnostic efficacy of serum cystatin C levels was evaluated through non-para-
metric receiver operating characteristic (ROC) analysis. The risk factors for changes
in serum cystatin C levels were confirmed using multivariate regression analysis.
With 24-hr urine creatinine clearance (Ccr) as the reference for GFR, 1/cystatin C
(r=0.702, P<0.001) showed a significantly higher correlation with Ccr than 1/crea-
tinine (r=0.665, P<0.001). Multivariate correlation analysis demonstrated that the
clinical parameters for increased serum cystatin C are a higher stage of chronic kid-
ney disease, older age, use of allopurinol, and lower high density lipoprotein-choles-
terol. The area under the curve (AUC) at ROC plots identified that of serum cystatin
C was significantly greater than that of serum creatinine (AUC 0.804 of cystatin C
and AUC 0.745 of creatinine). The study suggests that serum cystatin C is a reliable
endogenous marker for the assessment of renal function or GFR in gout patients
with renal impairment. 
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(10), and coronary angiopathy (11). 
Gout is an inflammatory rheumatic disease characterized
by deposition of crystallized monosodium urate, and uric acid,
within the joints. It is frequently associated with hyperuri-
cemia (12). The spectrum of renal diseases in gout patients
includes urate stones, acute uric acid nephropathy, and chron-
ic urate nephropathy. Chronic urate nephropathy may be asso-
ciated with a series of complicating factors, such as hormon-
al changes, insulin resistance, therapeutic drug management
for gout, and microvascular damage from untreated hyper-
tension, rather than simply from excessive depositions of uric
acid within renal tissues. Whatever the underlying of mech-
anism of renal disease in gout patients, individuals with gout
have renal problems. 
Currently, there are no clinical studies regarding the poten-
tial of using serum cystatin C to predict renal impairment in
gout patients. Therefore, our study was designed 1) to com-
pare diagnostic accuracy between serum cystatin C and serum
creatinine and 2) to identify non-renal determinants associ-
ated with serum cystatin C in patients with gout. 
MATERIALS AND METHODS
Subjects 
For this study, 68 male Korean gout patients with renal
impairment from the outpatient clinic of the Department of
Rheumatology at Daegu Catholic University Medical Cen-
ter were enrolled who fulfilled the preliminary criteria for
the classification of primary gout put forth by the American
College of Rheumatology (13). Patients who participated in
this study gave informed consent for review of their medical
records and use of urine and blood samples. This study was
approved by the Institutional Review Board Committee of
the Daegu Catholic University Medical Center. 
Exclusion criteria were as follows; patients on dialysis treat-
ment, those with chronic renal disease at either stage IV or
V according to guidelines proposed by the National Kidney
Foundation of the United States through its Kidney Disease
Outcomes Quality Initiative (K/DOQI) program (14), and
individuals with diabetic nephropathy or hypertensive neph-
ropathy. Based on the K/DOQI guidelines, patients enrolled
in this study were assigned to one of three groups; normal
GFR (≥90 mL/min/1.73 m2 and persistent albuminuria;
stage 1 of chronic kidney disease [CKD]), mildly decreased
GFR (60-89 mL/min/1.73 m2 and persistent albuminuria;
stage 2 of CKD), and moderately decreased GFR (30-59 mL/
min/1.73 m2; stage 3 of CKD).
Methods 
Blood was sampled from a forearm vein after midnight
fasting of 12-hr and stored at -70℃ until laboratory tests
were performed. And spot urine collection was simultane-
ously acquired. Twenty four-hours urine collection was per-
formed before the visit to the outpatient clinic for 1 day. Body
mass index (BMI, kg/m2) was assessed. Disease duration in
patients was estimated by examining medical records and
interviewing individual patients. 
Serum creatinine, serum cystatin C, blood urea nitrogen,
serum uric acid, fasting glucose, lipid profiles such as total
cholesterol, high density lipoprotein cholesterol (HDL-choles-
terol), low density lipoprotein cholesterol (LDL-cholesterol),
and triglyceride, erythrocyte sediment rate (ESR), and C-reac-
tive protein (CRP) were assessed from blood samples at the
time of enrollment in this study. Serum creatinine concen-
tration was determined by the kinetic Jaffe method accord-
ing to the manufacturer’s instructions (Cobas Intergra, Roche,
Switzerland). The quantitative measurement of cystatin C
in human serum was performed using the HiSenseTM latex-
enhanced turbidimetric immunoassay cystatin C kit (HBI
Co, Anyang, Korea). The degree of agglutination between
latex particles coated with antibodies specific for human cys-
tatin C and serum cystatin C levels is closely correlated with
the concentration of cystatin C in the sample. An optical den-
sity reading at 660 nm of the aggregates was used to calcu-
late the concentration of serum cystatin C. 
GFR was estimated from creatinine clearance (Ccr) using
a 24-hr urine collection in the subjects. The propriety of the
urine collection was referred from the guideline that daily
creatinine excretion should be 20 to 25 mg/kg of lean body
weight in male adults. Estimates of GFR were corrected for
a body surface area of 1.73 m2 using the method of DuBois
and DuBois. Ccr was used as the reference GFR to assess the
diagnostic efficacy of the test. 
Statistic analysis 
The data are presented as mean±standard deviation (SD)
or number (n) and proportion (%). The differences in contin-
uous variables among the three stages of renal function were
compared by ANOVA test. Linear correlations were verified
using the Pearson correlation test between continuous vari-
ables or using Spearman’s correlation analysis between con-
tinuous and non-continuous variables. After simple linear
regression analysis, confounding factors related to serum cys-
tatin C concentration were reanalyzed using multivariate
regression analysis.
Non-parametric receiver operating characteristic (ROC)
analyses were performed to evaluate diagnostic values of indi-
vidual parameters generated by graphically plotting sensitivi-
ty versus 1-specificity. The diagnostic accuracy of the test is
measured by the area under the curve (AUC). Statistical sig-
nificance is considered a value of P<0.05. All statistical anal-
yses were performed using SPSS version 12.0 software (SPSS
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RESULTS 
Basic clinical characteristics of enrolled patients 
A total of 68 male gouty patients with renal impairment
(54.6±11.5 yr of mean age and 6.4±5.6 yr of mean disease
duration) were enrolled in this study. Clinical parameters relat-
ed to the characteristics of patients and renal function were
assessed; these included age at study, disease duration, body
mass index (BMI), serum uric acid, uses of medications for
gout such as colchicine, allopurinol, benzbromarone, and non-
steroidal anti-inflammatory drugs (NSAIDs), lipid profiles,
fasting glucose, ESR, CRP, serum cystatin C levels, serum
creatinine levels, and Ccr (Table 1). In this study, we assigned
enrolled patients to one of three groups; 28 patients were in
the stage 1 of CKD, 22 patients in stage 2 of CKD, and 18
patients in stage 3 of CKD. 
The differences in clinical parameters between the three
groups were analyzed by ANOVA test. The results showed
significant differences in age at study (49.1±10.6 vs. 56.1±
9.7 vs. 61.1±11.3, P=0.001), serum cystatin C (0.9±0.2
vs. 1.1±0.2 vs. 1.4±0.4, P<0.001), serum creatinine (1.0
±0.2 vs. 1.1±0.2 vs. 1.4±0.3, P<0.001), and blood urea
nitrogen (17.2±5.9 vs. 15.5±4.3 vs. 22.1±5.8, P=0.001)
among three groups. However, clinical parameters such as
disease duration, BMI, serum uric acid, total cholesterol, HDL-
cholesterol, LDL-cholesterol, triglyceride, fasting glucose,
CRP, and ESR did not reveal significant differences among
the three groups (data not shown). 
Association of serum cystatin C and serum creatinine for
GFR with Ccr
The measured renal parameters, both serum cystatin C and
serum creatinine, were significantly correlated with GFR of
Ccr (Fig. 1). The correlation coefficient between 1/cystatin C
and Ccr (r=0.702, P<0.001) was higher than that between
1/creatinine (r=0.665, P<0.001) and Ccr (Fig. 1). A signifi-
cant correlation between serum creatinine and serum cystatin
C was also identified (r=0.815, P<0.001).
Clinical and laboratory parameters related with serum
cystatin C
We also identified non-renal determinants associated with
serum cystatin C in this study using simple linear correlation
analysis. Among all patients, serum cystatin C was closely
related with stages of renal function (r=0.576, P<0.001), age
*Estimated according to K/DOQI guideline.
SD, standard deviation; BMI, body mass index; HDL, high density lipop-
rotein; LDL, low density lipoprotein; NSAID, non-steroidal anti-inflamma-
tory drugs; GFR, glomerular filtration rate; Ccr, Creatinine clearance. 
Clinical and biochemical parameters Mean±SD 
Age (yr) 54.6±11.5
Disease duration (yr) 6.4±5.6
BMI (kg/m
2) 25.2±2.7
Serum cystatin C (mg/L) 1.1±0.34
Blood urea nitrogen (mg/dL) 18.0±6.0
Serum creatinine (mg/dL) 1.1±0.30
Creatinine clearance (mL/min/1.73 m
2) 88.9±36.4
Serum uric acid (mg/dL) 5.7±2.1
Total cholesterol (mg/dL) 189.0±36.0
HDL-cholesterol (mg/dL) 49.5±13.9
LDL-cholesterol (mg/dL) 121.6±31.9
Triglyceride (mg/dL) 172.9±86.3
Fasting glucose (mg/dL) 98.2±19.5
C-reactive protein (mg/dL) 2.6±4.1
Erytherocyte sediment reaction (mm/hr) 9.1±7.6
Medical therapy, No. (%)
Colchicines 63  (92.6)
Allopurinol 38  (55.9)
Benzbromarone 32  (47.1)
NSAIDs 58  (85.3)
Renal functional status*, No. (%)
Stage 1 28 (41.2) 
Stage 2 22 (32.3) 
Stage 3 18 (26.5) 
Table 1. Characteristics of clinical and biochemical parameters
in gout patients with renal impairment (n=68)
Fig. 1. Correlation between the 1/serum cystatin C and 1/serum creatinine for GFR estimated by Ccr. 
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at study (r=0.586, P<0.001), the use of allopurinol (r=0.406,
P=0.001), the use of benzbromaron (r=-0.329, P=0.006),
serum uric acid (r=0.379, P=0.001), ESR (r=0.364, P=0.002),
CRP (r=0.279, P=0.021), and HDL-cholesterol (r=-0.265,
P=0.033). Multivariate regression analysis identified that
more advanced renal stage (B=0.140, P=0.001), older age
(B=0.011, P<0.005), use of allopurinol (B=0.218, P=0.007),
and lower HDL-cholesterol (B=-0.005, P=0.015) were asso-
ciated with higher serum cystatin C in gout patients (Table 2).
Correlation for clinical and biochemical parameters accord-
ing to renal function was assessed in each three groups. Some
clinical parameters, such as the use of allopurinol (r=0.447,
P=0.017), serum uric acid (r=0.419, P=0.027), and CRP (r=
0.477, P=0.010) for stage 1 of CKD, only age at study (r=
0.530, P=0.011) for stage 2, and age at study (r=0.517, P=
0.028), the use of allopurinol (r=0.497, P=0.036), BUN (r=
0.474, P=0.047), and ESR (r=0.677, P=0.002) were signifi-
cantly associated with serum cystatin C. However, Multivari-
ate regression analysis for each renal function group showed
only age of study was significantly correlated with serum cys-
tatin C at both stage 2 and stage 3 of CKD (P=0.011 and P=
0.018, respectively), although parameters related with serum
cystatin C could not be identified. 
Diagnostic accuracy of serum cystatin C in gout 
The diagnostic accuracy of serum cystatin C was evaluated
using a non-parametric ROC plot (Fig. 2). The results showed
that the AUC for serum cystatin C had greater areas com-
pared with that of serum creatinine (AUC 0.804, P<0.001
vs. AUC 0.745, P=0.001). This findings demonstrated serum
cystatin C in gout patients has more diagnostic accuracy com-
pared with serum creatinine. 
DISCUSSION 
Serum cystatin C has been recognized as a reliable endoge-
nous index of GFR, since its introduction in 1985 (5, 6). In
addition, more sensitive indicators of GFR or renal function
have been identified in a variety of diverse systemic diseases
including nephropathy in type 2 diabetes mellitus (8), hyper-
tensive nephropathy (9), solid organ transplantation (10), and
coronary angiopathy (11). Few studies have investigated serum
cystatin C as an endogenous marker of renal function in rheu-
matic diseases other than rheumatoid arthritis (15, 16). This
is the first study to investigate the clinical application of serum
cystatin C to assess renal function in gout patients with renal
impairment. We found that serum cystatin C is closely asso-
ciated with serum creatinine and a good potential marker of
GFR in gout patients. 
Gout is a common, manageable medical disease related to
other systemic rheumatic diseases and has a wide spectrum of
clinical features, ranging from acute gouty arthritis to chronic
tophaceous gout. This disease is frequently associated with
hyperuricemia (defined as a serum urate concentration over
7 mg/dL) due to overproduction or underexcretion of urate,
or a combination of both. The physician should pay careful
attention to the development of associated comorbidities,
such as chronic renal diseases, cardiovascular diseases, or meta-
bolic syndrome. Of special clinical interest is the association
between gout and chronic renal diseases. However, some de-
bate remains as to whether impairment of renal function is
related to complicating factors such as hormonal changes,
insulin resistance, therapeutic drugs, and untreated hyperten-
sion, or to excessive depositions within renal tissue leading
to renal impairment, cell death and tissue hypoxia by hype-
ruricemia (17). Talbott and Terplan (18) presented diverse
histopathological findings in the biopsies and autopsy from
279 gout patients, and identified both clinicolaboratory and
pathologic findings. Murray and Goldberg (19) showed that
hyperuricemia was a primary cause of chronic interstitial ne-
CI, confidence interval.
Coefficients for serum cystatin C
B (95% CI for B)
Parameters
P
Stage of renal function 0.140 (0.141, 0.303) 0.001
Age (yr) 0.011 (0.006, 0.017) <0.001
Use of allopurinol  0.218 (0.061, 0.374) 0.007
HDL-cholesterol (mg/dL) -0.005 (-0.009, 0.001) 0.015
Serum uric acid (mg/dL) 0.024 (-0.009, 0.057) 0.146
Use of benzbromarone  0.078 (-0.072, 0.229) 0.220
ESR (mm/hr) 0.005 (-0.004, 0.014) 0.276
CRP (mg/dL) -0.006 (-0.021, 0.010) 0.479
Table 2. Multivariate regression analysis for clinical and labora-
tory parameters associated with serum cystatin C
Fig. 2. Comparison between serum cystatin C (solid line) and serum
creatinine (dotted line) in gout patients by nonparametric ROC plot
analysis. The AUC for serum cystatin C and creatinine were 0.804
and 0.745, respectively.
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phritis in a retrospective study of 101 patients. Recent study
determined that hyperuricemia may contribute to the devel-
opment of chronic gouty nephropathy as well as play a cru-
cial role in the progression of renal pathology (17). 
Until now, traditional measures for assessing renal function
such as measuring serum creatinine have been widely used
in gout patients, although they have some limitations for
accurate estimation of GFR. Here, we evaluated the diagnos-
tic efficacy and accuracy of using serum cystatin C levels to
estimate GFR and compared these results to those obtained
using traditional renal function indicators such as serum cre-
atinine and Ccr. Analysis for linear associations showed that
reciprocal cystatin C levels correlate well with Ccr of 24 hr
urine (r=0.702). In addition, the level of cystatin C is better
correlated with Ccr than the reciprocal creatinine level (r=
0.665) (Fig. 1). Our results from 68 male gout patients indi-
cate that serum cystatin C is a novel and reliable marker of
GFR. Zahran et al. (20) reviewed a number of studies to com-
pare the diagnostic accuracy of serum cystatin C levels and
serum creatinine levels in many clinical situations, includ-
ing transplant patients, patients with native kidney disease,
adults with native kidney disease, and pediatric patients with
native kidney disease (20). Their finding that serum cystatin
C was superior to serum creatinine remains controversial;
many investigators prefer to use serum cystatin C rather than
serum creatinine as an index of GFR (1, 7, 20). Our study
found that the diagnostic accuracy of serum cystatin C levels
were superior to that of serum creatinine using a ROC curve. 
The weaknesses of traditional measures of GFR including
serum creatinine have been recognized (1). Although serum
creatinine has became the most popularly used serum marker
of renal function, serum creatinine may be unreliable because
they are frequently affected by muscle mass, age, gender, and
aberrant renal tubular regulation of serum creatinine result-
ing in an overestimation of GFR. Using serum cystatin C
levels has some advantages over serum creatinine and creati-
nine-based calculated GFR formulas, in that serum cystatin
C levels are independent of age, gender, muscle mass, and
renal tubular secretion (1). Tenstad et al. (21) found that the
renal plasma clearance of cystatin C correlated well with GFR
using 51Cr-EDTA with a linear correlation coefficient of 0.99.
Given these characteristics, cystatin C can be considered to
be an ideal indicator of GFR. The present study also found
that serum cystatin C showed a good inverse correlation to
Ccr in gout patients (r=0.702, P<0.001). 
It has long been known that cystatin C levels are not highly
influenced by confounding factors, such as diet, nutrition, or
inflammatory status, whereas measurements for GFR based
on creatinine levels, including the MDRD or C&G formu-
las, have substantial limitations such as age, sex, muscle mass,
ethnicity, and methodology of determining serum creatinine
level (1) However, cystatin C production was not thought to
be affected by any factors until several authors demonstrated
that serum cystatin C could be affected by both rheumatoid
factor (22) and high doses of glucocorticoid (23). Addition-
ally, indirect evidence, including decreasing cystatin C in asth-
mathic patients after cyclosporine therapy (24) and the posi-
tive correlation between CRP and cystatin C levels in large
populations indicates that inflammatory status may also con-
tribute to changes in serum cystatin C levels (25). In the pre-
sent study, we assessed whether certain demographic and clini-
cal factors were correlated with serum cystatin C levels among
all enrolled patients. The data from our analyses indicates
that the stage of renal disease, the age of patients at the time
of study, serum uric acid, and HDL-cholesterol all influence
the serum cystatin C level. In addition, allopurinol-treated
patients have a tendency to have higher serum cystatin C lev-
els. It may be considered that gout patients with renal impair-
ment have allopurinol rather than benzbromarone as a uric
acid lowering agent. Interestingly, our data illustrated a weakly
positive association between ESR and serum cystatin C levels.
This finding suggests that serum cystatin C can be influenced
by inflammatory changes, which is in agreement with results
of some previous studies (24, 25), but in contrast to the data
of others (15). These conflicting results necessitate further
investigation into the effects of acute phase reactants such as
ESR and CRP on changes in the levels of serum cystatin C.
In addition, only age at study was significantly correlated
with serum cystatin C at subgroup analysis according to renal
function status. This discrepancy between whole enrolled
patients and each group patients may be resulted from small-
sized populations.  
Our study evaluated the diagnostic performance of serum
cystatin C using Ccr as a reference GFR, even though the limi-
tations of this technique were highlighted in previous stud-
ies (26, 27). However, Herget-Rosenthal et al. (28) discussed
creatinine clearance for GFR as an equivalent marker of true
GFR, likening it to different ‘‘gold standard’’ methods of GFR
including inulin, 125I-iothalamate, and 99mTc-DTPA. In their
study, cystatin C was found to be an accurate index of GFR
in 110 renal transplantation patients. Several studies regard-
ing cystatin C as diagnostic index of renal function in renal
transplant patients using Ccr as a reference GFR have been
performed, although the accuracy of serum cystatin C and
serum creatinine for evaluating GFR differed between the
various studies (28). Finally, some studies have demonstrat-
ed similar diagnostic performances of serum cystatin C and
serum creatinine levels using different GFR references such
as inulin (29) and 51Cr-EDTA (30).  
Data derived from our cross-sectional study in 68 male gout
patients with renal impairment illustrates that the serum
cystatin C level is a novel and reliable marker for accurately
predicting GFR that is superior to serum creatinine. This is
the first study to demonstrate the clinical application of serum
cystatin C levels in the field of gout, one of the inflammato-
ry rheumatic diseases. In addition to renal parameters in gout
patients, the results of this study revealed an association bet-
ween non-renal components such as allopurinol use and HDL-Cystatin C as a Marker for Renal Function in Gout Patients 47
cholesterol level and serum cystatin C. In the realm of inflam-
matory rheumatic diseases such as rheumatoid arthritis and
gout, renal issues are continuous and prominent. There are
some limitations for this study. The characteristics or patterns
of changes of serum cystatin C level were not observed in this
study because of limitation of cross-sectional study. And this
study could not reveal relationship between serum cystatin
C and inflammatory status of acute or interval stage of gout
or serologic markers, such as CRP, ESR, or serum amyloid.
To overcome these limitations, well-designed longitudinal
study for serum cystatin C will be necessary in larger popu-
lation. 
In conclusion, serum cystatin C is a reliable endogenous
marker for detection of renal impairment and estimation of
true GFR. To conclusively determine the diagnostic value
of serum cystatin C levels for monitoring renal function of
gouty patients, further prospective studies in a larger study
population are needed. 
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